EXPIRED
National Institutes of Health (NIH)
National Institute on Minority Health and Health Disparities (NIMHD)
U54 Specialized Center- Cooperative Agreements
October 17, 2023 - This RFA has been reissued as RFA-MD-24-001
June 21, 2023 - Notice of Pre-Application Technical Assistance Webinar for RFA-MD-23-011, "NIMHD Centers of Excellence in Investigator Development and Community Engagement (P50 - Clinical Trial Optional). See Notice NOT-MD-23-017
NOT-MD-23-006 - Notice of Correction to the Eligible Organizations, Number of Applications, and Component Type to Use in the Multi-Project Application Instructions for RFA-MD-23-001, "Research Centers in Minority Institutions (RCMI) (U54 Clinical Trial Optional)"
NOT-OD-22-189 - Implementation Details for the NIH Data Management and Sharing Policy
NOT-OD-22-195 - New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023
NOT-OD-22-198 - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023
NOT-OD-23-012 - Reminder: FORMS-H Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available
The purpose of the Research Centers in Minority Institutions (RCMI) Program is to expand the national capacity for research in the health sciences by providing cooperative agreement support to institutions that offer doctorate degrees in the health professions or in a health-related science and have a documented historical and current commitment to educating underrepresented students, and for institutions that provide clinical services to medically underserved communities. The primary goals of RCMI specialized center awards are to: (1) enhance institutional research capacity to conduct world-class basic biomedical, behavioral, population and/or clinical research; (2) enable all levels of investigators at the recipient institution to become more successful in obtaining competitive extramural support, especially from NIH, for research on diseases and conditions that disproportionately impact populations that experience health disparities; (3) foster institutional environments conducive to research career development and enhancement for post-doctoral fellows, junior faculty, and other early-stage investigators; (4) enhance the tools for and conduct of research generally and specifically for improving minority health and reducing health disparities; and (5) establish sustainable partnerships with community-based organizations to promote research efforts and the dissemination of research findings.
January 30, 2023
Application Due Dates | Review and Award Cycles | ||||
---|---|---|---|---|---|
New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
March 01, 2023 | March 01, 2023 | March 01, 2023 | June 2023 | August 2023 | December 2023 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
No late applications will be accepted for this Funding Opportunity Announcement.
Not Applicable
It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Background
NIH established the Research Centers in Minority Institutions (RCMI) program in 1985 in response to Congressional interest in expanding the national capability for research in the health sciences by providing support to institutions that offer doctoral degrees in the health professions or health-related sciences and have an historical and current commitment to educating underrepresented students or providing health care services to medically underserved communities. NIMHD recognizes the important role these institutions have played in supporting scientific research, particularly on diseases or conditions that disproportionately impact racial/ethnic minorities and other U.S. populations that experience health disparities. Although these institutions are uniquely positioned to engage minority populations in research and in the translation of research advances into culturally competent, measurable and sustained improvements in health outcomes, they often lack sufficient capacity to conduct and sustain cutting-edge health-related research.
NIH Interest In Diversity
Every facet of the United States scientific research enterprise from basic laboratory research to clinical and translational research to policy formation requires superior intellect, creativity and a wide range of skill sets and viewpoints. NIH’s ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH's mission (see NOT-OD-20-031). This funding opportunity provides support for participating RCMI institutions to facilitate the development of research capacity, research education of students, and the ability of faculty to pursue basic biomedical, behavioral, population and/or clinical/health services research, including but not limited to research related to minority health and health disparities.
Programmatic Approach
The primary goals of RCMI specialized center awards are to: (1) enhance institutional research capacity to conduct world-class basic biomedical, behavioral, population and/or clinical/health services research; (2) enable all levels of investigators at the recipient institution to become more successful in obtaining competitive extramural support, especially from NIH, for research on diseases and conditions that disproportionately impact populations that experience health disparities; (3) foster institutional environments conducive to research career development and enhancement for post-doctoral fellows, junior faculty, and other early-stage investigators; (4) enhance the tools for and conduct of research generally and specifically for improving minority health and reducing health disparities; and (5) establish sustainable partnerships with community-based organizations to promote research efforts and the dissemination of research findings.
Centers are expected to support research projects with an explicit focus on one or more of the following scientific areas: basic biomedical research, behavioral research or population science, and clinical/health services research. Projects in the behavioral or population science and clinical/health services research focus areas are expected to emphasize minority health and health/healthcare disparities. Accordingly, such projects must include a focus on the health of one or more racial or ethnic minority groups that experience health and or health care disparities: Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, and other health disparity populations, including low socioeconomically status, medically underserved or rural populations, and sexual and gender minorities. The basic biomedical research focus area does not have this requirement.
Information about the research priorities of NIMHD is available at the following link: NIMHD Research Framework, https://nimhd.nih.gov/about/overview/research-framework/nimhd-framework.html. Minority health refers to distinctive health characteristics and attributes of racial/ethnic minority groups in the U.S. Minority health research is the scientific investigation of these distinctive health characteristics and attributes. Research may focus on risk or protective factors for conditions where outcomes may be worse or better, respectively, compared to the general population, including projects that evaluate mechanisms and interventions to sustain or improve a health advantage. Research may also examine mechanisms and develop and evaluate interventions to reduce health and/or health care disparities within a particular group (or within a health care setting providing care), defined as a health difference that adversely affects disadvantaged populations based on one or more of the following categories of health outcomes:
Minority health and health disparities research is a multi-disciplinary field of study devoted to gaining greater scientific knowledge about the influence of health determinants and defining mechanisms that lead to disparities and how this knowledge is translated into interventions to reduce or eliminate adverse health differences.
The RCMI program allows flexibility at the applicant institution with respect to the types of research resources required to accomplish research and investigator development goals. The most important criterion for inclusion of any component in the proposed Center is the extent to which the activity or resource will enable the institution to achieve the stated goals.
Required and Optional Cores of an RCMI Specialized Center:
The following components are required for each Center:
In addition to these required components, applications may also include the following optional core:
Descriptions of Required Components
Administrative Core
The Administrative Core must be directed by the PD(s)/PI(s) of the Center. This core will provide administrative and logistical support for all Center activities, including career enhancement activities for post-doctoral fellows and junior investigators, and foster synergy with other ongoing career development activities at the institution including any funded through other NIH grants. Resources may be requested to support seminars, workshops, and other career enhancement activities that promote the recruitment, advancement, and retention of investigators in biomedical research careers. In addition, this core oversees an assessment of each proposed activity/core and the impact of the Center as a whole in terms of: 1) enhancing the institutional research capacity and environment necessary to facilitate biomedical research in the areas identified by the applicant; 2) increasing productivity of investigators in peer-reviewed publications and discovery; and 3) increasing the institution's overall success in applying for and obtaining extramural research funding, especially from NIH. Successful applicants will be expected to work closely with the RCMI Coordinating Center (RFA-MD-20-007) to develop and implement common metrics and share data on programmatic outcomes for each Center component as part of this evaluation process.
The Center PD(s)/PI(s) will also be expected to attend periodic meetings convened by the RCMI Coordinating Center to showcase the science being conducted at the Centers, promote collaboration amongst Centers and other research consortia and networks such as the RCMI Clinical Research Networks, share best practices for Center operations, and provide information about special funding opportunities supported by other NIH Institutes, Centers and Offices (see NOT-MD-21-004, NOT-MD-21-021, NOT-MD-21-022, and RFA-HG-22-026, for recent examples). RCMI Centers are encouraged to pursue supplement or funding opportunities from other Institutes, Centers and offices at NIH.
Applicants are encouraged to plan for developing or utilizing existing data standards and using common data elements (CDEs) and measures across Research Projects and pilot projects as applicable in collaboration with the RCMI Coordinating center, including CDEs from the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org).
Research Capacity Core: Methodology, Laboratory Technologies, Biostatistics, Data Science, Community-Engaged Methods, and Core Research Resources
The goal of the Research Capacity Core is to enhance the quality and productivity of the research projects proposed, and the pilot projects funded, as well as link RCMI faculty and scholars with other researchers at the applicant institution. Applicants may request resources to assist investigators with developing design and analysis plans for studies. Such resources may include faculty-level expertise in research methodology, specialized laboratory techniques, statistics, data science, health informatics, and/or community-engaged methods. Applicants may also propose activities that bridge research in study design, biostatistics, and research ethics with other NIH supported centers including those of the Clinical and Translational Science Awards (CTSA), Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research, Resource Centers for Minority Aging Research Centers (NIA), the Multiple Chronic Disease Research Centers (NIMHD), RCMI Clinical Networks, Center for AIDS Research (CFARs) or other consortia. If biomedical informatics resources are requested, applicants should consider both internal, intra-institution and external interoperability to allow for communication among RCMI awardees and with other research partners (e.g., universities, government, clinical research networks, and pharmaceutical companies).
If core research resources are requested, they must be for multiple users, including infrastructure applicable to various disciplines in the institution (e.g., medicine, nursing, dentistry, pharmacy, public health, biostatistics, social sciences, epidemiology, bioengineering, or others) for the benefit of researchers and research projects. Standard operating procedures are required, and participation in national or international quality control and standardization efforts is encouraged where appropriate. Proposed resources should be fully justified within the context of the overall program goals, and not duplicate locally available resources. The level of support requested must be justified by the projected use by biomedical researchers from within the applicant institution. Laboratory equipment, supplies, statistical and database software, and personnel are all acceptable costs. Cost recovery for core support should be sought from funded investigators.
Minor alteration and renovation (A&R) to improve existing research/core laboratories or animal facilities are allowed. This FOA will provide up to $500,000 in direct costs for A&R in addition to the overall direct cost cap, only in year one of the award period, as a one-time cost expenditure for a center. Funds designated for A&R under this FOA cannot support construction, modernization, or major alterations and renovation of research facilities as defined in Section 10.1 of the NIH Grants Policy Statement. A&R costs will be approved only for facility improvements at the applicant organization. Proposed improvements at consortium sites are not allowed.
Investigator Development Core
Applicants must request support for the Investigator Development Core with a Pilot Project Program that: 1) allows the eligible institution's early career stage researchers to conduct their own research project that either generates preliminary data for subsequent submission of grant applications and/or results in a peer-reviewed research publication; or 2) completes an analytic project of existing data that leads to a peer-reviewed research publication and informs subsequent plans for submission of grant applications; or 3) develops new technologies that will better position the institution to conduct basic biomedical research. Such funds must be readily available and be accompanied by an organizational structure that supports full compliance with regulatory requirements. Pilot projects that focus on research related to diseases that disproportionately impact minority or other disparity populations, or that address health disparities are strongly encouraged.
Community Engagement Core
Applicants must describe activities designed to establish long-term relationships with community-based organizations in order to build mutual trust to address their health-related concerns, to promote participation in research and recruitment and retention of study participants, and to disseminate findings from research projects. The core will coordinate dissemination activities with community members, partner organizations, and relevant service organizations or policymakers, as well as the scientific community, including presentation of findings from research projects and pilot projects to translate findings into sustainable community and system-level changes at the local level and beyond. Core activities are expected to contribute to scientific advancements such as improved interventions based on local knowledge, improved cultural competence of investigators, and strengthened community-engaged research approaches.
Research Project(s)
Up to three research projects may be proposed in scientific focus areas of: 1) basic biomedical research, and/or 2) behavioral research and/or population science, and/or 3) clinical and health services research. In order to receive the maximum Center budget, applicants must propose one project in each of the three scientific focus areas. Any proposed behavioral research, population science, or clinical and health services research project(s) must serve to advance scientific knowledge as it relates to minority health and/or health disparities. Basic biomedical research projects do not have this requirement. For additional information on the research interest areas, please visit NIMHD website https://www.nimhd.nih.gov/programs/extramural/research-areas/index.html.
Applicants are encouraged to include projects of variable size and duration over the 5 years. While the Pilot Project Program in the Investigator Development Core focuses on early career stage investigators, the Research Projects may be led by more established investigators or senior scientists, or the most qualified scientist regardless of rank, at the applicant institution.
If research projects on SARS-CoV-2 and COVID-19-related topics are proposed, successful applicants will be expected to utilize resources developed by the RADx-UP Coordinating and Data Collection Center (CDCC) including NIH RADx-UP Common Data Elements - RADx-UP to collect common data elements and develop evaluation metrics and informational material to meet community needs on COVID-19.
Applicants are encouraged to plan for developing or utilizing existing data standards, sharing data and fostering collaborations with other research consortia and networks such as the RCMI Coordinating center for using common data elements (CDEs) and measures across Research Projects and pilot projects as applicable, including CDEs from the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org).
Description of Optional Core
Recruitment Core
This core may support the hiring of investigators who have track records of independent research support that includes current or recent support (within the last two years) by NIH R-series, P-series, and/or U-series awards, or other federal or non-federal awards and who can serve as mentors to junior investigators. Institutions should develop outreach and recruitment strategies intended to diversify the applicant pool by encouraging prospective applicants from underrepresented groups to apply (see, NIH's Notice of Interest in Diversity, NOT-OD-20-031). These new faculty members may be provided up to $250,000 direct costs per year for up to two years to augment institutional support to establish their research laboratories or program, acquire specialized equipment or partially support a specialized collaborator, and support postdoctoral fellows and technical assistants.
Applications Not Responsive to this FOA
Non-responsive applications will not be reviewed. Applicants are encouraged to reach out to the FOA scientific/research contact prior to submission to discuss whether their application is responsive.
Program Evaluation by NIMHD
The RCMI Specialized Research Centers program will undergo evaluation and assessment by the NIMHD. The evaluation of the program is distinct from an individual Center’s outcome evaluation (described in Section IV). While both evaluations address Center outcomes, they differ in scope (individual award vs. national program) and have different timelines and metrics (PD/PI defined vs. programmatic goals specified below). The program evaluation will be carried out within four years after the release of this FOA. Assessment will be developed based on institutional changes that will include, but are not limited to:
The findings of this program evaluation will determine whether the program is continued as configured, continued with modifications, or discontinued. Should the findings indicate that the program is no longer needed or is not effective in meeting the overall goals, NIMHD may also consider terminating the program.
Technical Assistance Webinar
NIMHD will conduct a Technical Assistance webinar for prospective applicants on January 20, 2023 at 3:00 PM EST. The webinar connections will open 15 minutes in advance of the start time. NIMHD staff members involved in this FOA will provide orientation and technical assistance to potential applicants by explaining the goals and objectives of the RCMI Specialized Centers initiative and answering questions from attendees. Prospective applicants are encouraged to send questions, preferably at least 24 hours prior to the webinar, to the Scientific/Research Contact, Dr. Nathan Stinson, at stinsonn@mail.nih.gov and/or Dr. Rina Das, at dasr2@mail.nih.gov
To Join the webinar, interested persons can use the WebEx meeting link or other connection information, as follows:
Join Webex meeting
Meeting number (access code): 2552 530 0349 Meeting password: RCMI
Join from a video system or application
Dial 25525300349@nih.webex.com">25525300349@nih.webex.com
You can also dial 173.243.2.68 and enter your meeting number.
Tap to join from a mobile device (attendees only)
+1-650-479-3208,,25525300349## Call-in toll number (US/Canada)
See Section VIII. Other Information for award authorities and regulations.
Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs.
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
Optional: Accepting applications that either propose or do not propose clinical trial(s).
NIMHD intends to commit minimum of $10 million in FY 2023 to fund 2- 4 awards.
Center budgets are limited to $3,500,000 in annual direct costs, excluding alterations and renovation (A&R) costs in year 1 (see below) and recruitment costs in two designated years (see below). Applications with Research Projects in all three focus areas (basic biomedical research, behavioral research and/or population science, and clinical/health services research) may request the full $3,500,000. Applications with Research Projects in two focus areas may request up to $2,500,000 in annual direct costs. Applications with Research Projects in one focus area may request up to $1,500,000 in annual direct costs. Significant justification is expected if requesting the maximum limit.
This FOA will also provide up to $500,000 in direct costs for A&R in addition to the overall direct cost caps above, only in year one of the award period, as a one-time cost expenditure for a Center.
This FOA will also provide up to $250,000 in direct costs per year for Recruitment package in addition to the overall direct cost caps above, only in two pre-designated years of the award period for a Center.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.
1. Eligible Applicants
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
To be eligible for this FOA, the applicant institution must be a domestic institution located in the United States and its territories which:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
2. Cost Sharing
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
3. Additional Information on Eligibility
Number of Applications
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
Only one application (normally identified by having a Unique Entity Identifier (UEI) number or NIH IPF number) is allowed.
1. Requesting an Application Package
The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission
It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
The letter of intent should be sent to:
Yujing Liu, MD, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-7815
Email: liuyujin@mail.nih.gov
Page Limitations
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
Component | Component Type for Submission | Page Limit | Required/Optional | Minimum | Maximum |
---|---|---|---|---|---|
Overall | Overall | 6 | Required | 1 | 1 |
Admin Core | Admin Core | 6 | Required | 1 | 1 |
Research Capacity Core | Capacity Core | 6 | Required | 1 | 1 |
Investigator Development Core | Investigator Core | 6 | Required | 1 | 1 |
Community Engagement Core | Community Core | 6 | Required | 1 | 1 |
Optional Recruitment Core | Optional Core | 6 | Optional | 0 | 1 |
Research Projects | Projects | 12 | Required | 1 | 3 |
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.
The application should consist of the following components:
Overall Component
When preparing your application, use Component Type Overall .
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424(R&R) Cover (Overall)
Complete entire form.
PHS 398 Cover Page Supplement (Overall)
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Research & Related Other Project Information (Overall)
Follow standard instructions.
Other Attachments: The application must include a single attachment titled "Institutional Information" that provides a description and evidence of the institution's explicit accomplishments in the education of students from backgrounds nationally underrepresented in biomedical research, or efforts to provide services to medically underserved communities.
Project/Performance Site Locations (Overall)
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Research and Related Senior/Key Person Profile (Overall)
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
Budget (Overall)
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
The PD/PI must serve a minimum level of effort of at least 3.6 person months (PM) unless there are two or more PD/PIs in multiple PD/PI applications. In such a case, the minimum level of effort can be reduced to 2.4 PM for each multiple PD/PI. If a PD/PI serves a role in multiple components, the effort that is served in each component can be combined to meet the requirement.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
PHS 398 Research Plan (Overall)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.
Specific Aims: Describe the specific aims for the Center and summarize how the proposed components and activities will: 1) enhance institutional research capacity to conduct world-class basic biomedical, behavioral and/or clinical research; 2) enable all levels of investigators to become more successful in obtaining competitive extramural research support, especially from NIH, particularly for research on diseases and conditions that disproportionately impact minority and health disparity populations; 3) foster environments conducive to career development and enhancement for post-doctoral fellows, junior faculty, and other early stage investigators; (4) enhance the tools for, conduct of, and dissemination of research generally and specifically for advancing minority health and preventing and eliminating health disparities; and (5) establish sustainable relationships with community-based organizations that will partner with the RCMI Institution.
Research Strategy:
Provide a Program Overview describing the scientific focus area(s) to be supported by the Center (i.e., basic science, and/or behavioral research, and/or clinical/health services research) and the rationale for seeking support for the proposed focus area(s) within the context of the applicant institution's priorities, long-range goals and vision for health-related research. If multiple areas are proposed, provide a rationale for the importance of the Center's research program as a whole to the larger goals of the applicant institution. Describe and justify how existing and requested resources will be utilized and leveraged to implement the institutional plan to develop, expand, and maintain an environment and framework suitable for achieving the objectives of the Center.
Summarize relevant organizational, educational, and scientific strengths and weaknesses at the applicant institution and describe how the proposed activities will address perceived research infrastructure needs. Describe the overall goals for the Center during the proposed project period, the specific institutional commitments that will be made to help achieve those goals, and the key activities that will be conducted to achieve each of the proposed goals.
For renewal applicants, provide a Progress Report on previous RCMI funding. In addition to the overall section, a progress report can be also included for each component of the application, when applicable.
Letters of Support:
Applications must include letters from the appropriate high-ranking applicant institutional official(s) that:
All other Letters of Support for all application components should be included within this section in the Overall component. Do not include letters of support in other components.
Applications that propose work with American Indian or Alaska Native populations, tribes or communities must include letters of support from the appropriate tribal officials and/or tribal organizations as applicable.
The Letters of Support attachment should begin with a table of letter authors, their institutions, and the type of each letter (institutional commitment or resources; collaboration or role in the project; potential or current user of a resource or service proposed in the application).
The following modifications also apply:
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.
The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
PHS Human Subjects and Clinical Trials Information (Overall)
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
PHS Assignment Request Form (Overall)
All instructions in the SF424 (R&R) Application Guide must be followed.
Administrative Core
When preparing your application, use Component Type Admin Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Administrative Core )
Complete only the following fields:
PHS 398 Cover Page Supplement (Administrative Core )
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Administrative Core )
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Administrative Core )
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Administrative Core )
Budget ( Administrative Core )
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Administrative Core )
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
The most commonly referenced Research Plan attachments are listed below for your convenience. FOA specific instructions are required for the Specific Aims and the Research Strategy in each component. FOA-specific instructions are optional for Letters of Support. Delete Letters of Support if there are no FOA-specific instructions.
Specific Aims: Describe the specific aims for the Administrative Core.
Research Strategy:
Describe how the Administrative Core will manage, coordinate and supervise the entire range of proposed activities; monitor progress; and ensure that component plans are implemented. Explain the roles and responsibilities of core personnel, including scientific leadership, administrative management, and coordination of proposed activities.
Describe the programmatic activities (e.g., seminars, workshops or other activities) that will be undertaken to support career enhancement for post-doctoral level professionals and junior faculty from a variety of disciplines. Describe the academic qualifications, research experience, and productivity of mentors, including those from other institutions. Provide evidence of how the proposed activities will be integrated across the institution.
Include a management plan describing the Center’s organizational and governance structure and plans to manage and, where necessary, reassign institutional resources among schools and/or departments to achieve Center goals. Describe the composition and roles of any committees proposed to help manage the Center activities. Each Center must have an Advisory Committee (AC). Depending on the scope and complexity of the center, the AC may consist of up to ten members. The AC should include representatives from the target communities, external scientific advisors with relevant expertise. The AC should review structure and progress and offer recommendations to the PD/PI(s) on an annual basis. New applications must describe the types of expertise of the members that will be recruited for the AC; however, applicants should not list potential AC members in the application or contact them prior to peer review. For renewal applications, list current AC members.
Include an Evaluation Plan to facilitate ongoing Center performance and project management to ensure successful completion of the stated aims. Describe how the evaluation will be conducted, principal performance measures and metrics to be used to assess achievement of short- and long-term goals of each core and project, and potential sources of data. The productivity of investigators, including those with pilot projects, should include monitoring related publications, grant applications and awards. The plan should address administrative functioning (process) as well as scientific and developing investigator accomplishments (outcomes). Describe key milestones and expected outcomes for each area, as appropriate.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
PHS Human Subjects and Clinical Trials Information (Administrative Core )
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
Research Capacity Core
When preparing your application, use Component Type Capacity Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Research Capacity Core)
Complete only the following fields:
Applicant Information
Type of Applicant (optional)
Descriptive Title of Applicant’s Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Research Capacity Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Research Capacity Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Other Attachment: If funds are requested for minor alterations and renovations, the application must include a single attachment titled " Alterations and Renovations " that provides:
A description of the functional units, including the size (dimensions) and square footage of each component (room, alcove, cubicle) that will be directly affected by the renovation project. Engineering criteria applicable to each component unit (mechanical, electrical, and utilities) must be included such as the number of air changes per hour, electrical power, light levels, hot and cold water, and steam. Applicants must also list appropriate architectural criteria (such as width of corridors and doors, surface finishes). All fixed equipment items requested for the renovated area must be listed and justified. If renovations to animal facilities are proposed, the proposed renovations must be related to the projected animal population by species and include the lines of authority and responsibility for administering the institution's animal care and use program. The role and composition of the Institutional Animal Care and Use Committee (IACUC) and how compliance with relevant laws, policies, and guidelines are achieved must also be included.
Line drawings of the proposed renovation(s) must be legible, with the scale clearly indicated and adequate to explain the project. Drawings must indicate size (dimensions), function, and net and gross square feet of space for each room. The total net and gross square feet of space to be renovated must also be given. The plan must indicate the location of the proposed renovation area in the building. Include the as-built drawings of the proposed renovation area and indicate any areas that will be demolished. Any changes or additions to existing mechanical and electrical systems must be clearly described in notes made directly on the plan or attached to the plan. Indicate the type(s) of new finishes to be applied to room surfaces. Applicants must relate the proposed renovations to the research projects that will use the facility and detailed cost estimates must be included. Provide vendor quotes when available.
Project /Performance Site Location(s) (Research Capacity Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Research Capacity Core)
In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Research Capacity Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Minor alteration and renovation (A&R) to improve existing research/core laboratories or animal facilities are allowed. This FOA will provide up to $500,000 in direct costs for A&R in addition to the overall direct cost cap, only in year one of the award period, as a one-time cost expenditure for a center. Funds designated for A&R under this FOA cannot support construction, modernization, or major alterations and renovation of research facilities as defined in Section 10.1 of the NIH Grants Policy Statement. A&R costs will be approved only for facility improvements at the applicant organization. Proposed improvements at consortium sites are not allowed.
PHS 398 Research Plan (Research Capacity Core)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: Describe the specific aims of the Research Capacity Core.
Research Strategy: Describe how the resources and services to be provided by the Core at the applicant institution will enhance the tools for, the conduct, quality and productivity of, and the dissemination of research generally, and especially for research projects and pilots seeking to advance minority health and prevent and eliminate health disparities.
Describe plans and processes for developing or utilizing existing standards and other means to maximize interoperability between internal and external systems and foster collaborations with other research consortia and networks. Include plans for using common data elements (CDEs) and measures across Research Projects and pilot projects as applicable, including CDEs from the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org).
Describe the services that the Research Capacity Core will provide, as applicable:
Resources and services that will be offered, with plans for their prioritization, availability, management and tracking. Plans to ensure inclusion of infrastructure applicable to various disciplines in the institution for the benefit of researchers and research projects across a broad range of health-related research areas.
The user pool for the requested resource that includes a description of the research projects, collaborators and funding sources.
Services for study design and analyses with methodological and statistical expertise to support research projects, pilot studies and other investigators.
Bioinformatics and data science support for data storage and common data elements.
Health informatics and data analytic support for data resources such as electronic health records, public use sources, clinical studies, or other sources of health data on minority and other disparity populations.
Common laboratory techniques to be used across basic science projects that require specialized skills.
Laboratory equipment that will be used by RCMI investigators and fellows with pilot grants.
Advice that may include but is not limited to conflict of interest, federal codes requirements, privacy and safety of research participants.
Integration of research ethics into core services.
Integration of resources with similar resources at the institution and any affiliates.
Support provided for operations, administration and research activities.
The process by which standards and other mechanisms will be developed and used to maximize interoperability between internal systems and systems in external organizations.
Interactions with the RCMI program and other partners.
Assessment of informatics performance with external partners- RCMI awardees, Clinical and Translational Science Awards (CTSA), Institutional Development Award (IDeA) Program Infrastructure for Clinical and Translational Research, Resource Centers for Minority Aging Research Centers (NIA), the Multiple Chronic Disease Research Centers (NIMHD) or other consortia.
Plans for cost recovery from funded investigators and/or specific institutional support for the core.
Any minor alteration and renovation (A&R) to improve existing research/core laboratories or animal facilities.
For renewal applications, it is important to state how the current requested research capacity support builds upon or is complementary to previous RCMI funding.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment of the Overall component in FORMS-H application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information (Research Capacity Core)
Not applicable
Investigator Development Core
When preparing your application, use Component Type Investigator Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Investigator Development Core)
Complete only the following fields:
Applicant Information
Type of Applicant (optional)
Descriptive Title of Applicant’s Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Investigator Development Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Investigator Development Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Investigator Development Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Investigator Development Core)
In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Investigator Development Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Applicants may request support for up to five pilot projects per year in the Pilot Project Program. The combined direct costs allocated to pilot projects and required to be expended in the Pilot Project Program is up to $250,000 per year. Direct costs for each pilot project may range from a minimum of $25,000 per year to a maximum of $50,000 per year for up to two years. The direct costs and project period for a pilot project may not exceed those for an NIH R03 grant.
Funds should not be requested to cover the cost of tuition, fees or stipends for students or trainees. Compensation for services rendered is allowable. Personnel and other costs needed to support the administration of the Pilot Project Program are also allowable Core costs.
PHS 398 Research Plan (Investigator Development Core)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: Describe the specific aims for the Investigator Development Core.
Research Strategy: The primary goal of the Investigator Development Core is to support the development of post-doctoral fellows, junior faculty, and other early-stage investigators in basic biomedical, behavioral, and/or clinical sciences through a Pilot Project Program. Eligible applicants should be at the senior post-doctoral or fellowship level or assistant professor or equivalent.
Describe the pool of potential applicants and how the core will promote the receipt of pilot project applications from individuals from diverse backgrounds, including those from underrepresented groups in the biomedical research workforce (see Notice of NIH’s Interest in Diversity, https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html).
Recipients of pilot funds will be expected to receive ongoing advice from RCMI faculty, meet on a regular schedule, participate in seminars and conduct their research pilot project. These investigators will be expected to work on publications based on their pilot project as well as collaborate on other projects. The goal is to successfully apply for external funding such as mentored K-award or equivalent and ultimately a R01 grant as appropriate to their career level.
Applicants should describe the plan to solicit and review proposals, prioritize the pilot projects for funding and to review their methodology and research performance. The description of the Pilot Project Program should include the scope; eligibility requirements; the limit on the dollars available and the number of years of support per pilot project; the solicitation, submission, review, and selection criteria and process; governance, oversight and evaluation procedures; and assurances that all pilot projects supported from this grant will comply fully with all applicable Federal policies, rules, and guidelines for research involving human subjects and vertebrate animals.
Do not include detailed proposals or descriptions of specific pilot projects, as pilot projects should not be selected until after the Center grant is awarded.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment of the Overall component in FORMS-H application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information (Investigator Development Core)
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
Community Engagement Core
When preparing your application, use Component Type Community Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Community Engagement Core)
Complete only the following fields:
Applicant Information
Type of Applicant (optional)
Descriptive Title of Applicant’s Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Community Engagement Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Community Engagement Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Community Engagement Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Community Engagement Core)
In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Community Engagement Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Community Engagement Core)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: Describe the specific aims for the Community Engagement Core.
Research Strategy: Without duplicating information in the Biographical Sketches, describe the leadership of this core, and the principles, policies, and practices that will guide its operation. Describe strategies for building and maintaining the coalition of local stakeholders designed to establish long-term relationships with community-based organizations and to promote participation in research including recruitment and retention of study participants. Describe how the Core will facilitate collaboration between coalition members and investigators on Research and Pilot projects. Describe the types of activities that will be conducted for the timely and appropriate dissemination of information generated by the Center, its research projects, pilot projects, and other activities for a broad range of audiences, including lay community audiences. Describe the expected outcomes of the proposed dissemination strategies and activities and how the impact of dissemination efforts will be assessed. Describe strategic planning processes to translate findings into sustainable community and system-level changes at the local level and beyond.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment of the Overall component in FORMS-H application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information (Community Engagement Core)
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
Recruitment Core (Optional)
When preparing your application, use Component Type Optional Core.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Recruitment Core)
Complete only the following fields:
Applicant Information
Type of Applicant (optional)
Descriptive Title of Applicant’s Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Recruitment Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Recruitment Core)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Recruitment Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Recruitment Core)
In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Recruitment Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Applicants may request up to $250,000 in direct costs per year for recruitment in two pre-designated years of the proposed project period.
PHS 398 Research Plan (Recruitment Core)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: Describe the specific aims for the Recruitment Core.
Research Strategy: If applicable, applicants should describe plans for recruiting and hiring additional research personnel that may be required to accomplish the goals of the center. This may include hiring of senior or mid-career investigators who have independent research support and can mentor junior investigators. These new faculty members may receive support to establish their research laboratories, acquire specialized equipment, and support postdoctoral fellows and technical assistants. If recruitment of new faculty members is proposed, the application must contain detailed planning and recruiting activities intended to diversify the applicant pool and encourage potential applicants from underrepresented groups to apply. The application must also describe the applicant's plans for advertisement, recruitment, interview and selection processes that are equitable and ethical. In addition, the applicant should describes career enhancement and retention plans. Applicants must include a proposed timetable specifying the expected hiring date for each new faculty and/or staff member.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment of the Overall component in FORMS-H application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information (Recruitment Core)
Not applicable
Research Project
When preparing your application, use Component Type Project.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. If required, the Data Management and Sharing (DMS) Plan must be provided in the Overall component.
SF424 (R&R) Cover (Research Project)
Complete only the following fields:
Applicant Information
Type of Applicant (optional)
Descriptive Title of Applicant’s Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Research Project)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Research Project)
Human Subjects: Answer only the Are Human Subjects Involved? and 'Is the Project Exempt from Federal regulations? questions.
Vertebrate Animals: Answer only the Are Vertebrate Animals Used? question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Research Project)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Research Project)
In the Project Director/Principal Investigator section of the form, use Project Role of Other with Category of Project Lead and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Research Project)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
Combined RCMI research project budgets should total 20-30% of maximum direct costs per year for the proposed center. Therefore, combined research project annual direct costs (not including consortium F&A costs) are limited to $450,000 for applications that encompass one research focus area, $750,000 for two research focus areas, and $1,050,000 for all three research focus areas.
PHS 398 Research Plan (Research Project)
Introduction to Application: For Resubmission applications, an Introduction to Application is allowed for each component.
Specific Aims: Describe the specific aims for the Research Project.
Research Strategy: All projects in the focus areas of behavioral research or population science and clinical/health services research must address research questions related to the field of minority health and/or health disparities and have a primary focus on one or more NIH-designated U.S. populations that experience health disparities. Comparison groups are not required for such studies but may be included as appropriate for the research question(s) posed. Community-engaged research approaches are encouraged when applicable but are not required for every project.
For research projects on SARS-CoV-2 and COVID-19-related topics, describe plans for working with the RADx-UP Coordinating and Data Collection Center (CDCC, RFA-OD-20-013) to submit common evaluation metrics on COVID-19 testing and vaccine uptake outcomes and implementation to the CDCC.
For the purposes of this FOA, projects in the basic biomedical research focus area, including proposed animal studies, are not required to have direct relevance to minority health or health disparities.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment of the Overall component in FORMS-H application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan. The Data Management and Sharing (DMS) Plan must be provided in the Overall component.
Appendix:
Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Human Subjects and Clinical Trials Information (Research Project)
When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the SF424 (R&R) Application Guide must be followed.
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
4. Submission Dates and Times
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
5. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
6. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
7. Other Submission Requirements and Information
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by NIMHD, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.
In order to expedite review, applicants are requested to notify the NIMHD Referral Office by email at mlaudesharp@mail.nih.gov when the application has been submitted. Please include the FOA number and title, PD/PI name, and title of the application.
Post Submission Materials
Applicants are required to follow the instructions for post-submission materials, as described in the policy.
1. Criteria
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) will not be evaluated at time of review.
A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Specific to this FOA: To what extent is the proposed project likely to (1) enhance institutional research capacity to conduct world-class basic biomedical, behavioral, and/or clinical research, and (2) enable all levels of investigators at the applicant institution to become more successful in obtaining competitive extramural support, especially from NIH, for research on diseases and conditions that disproportionately impact populations that experience health disparities?
In addition, for applications involving clinical trials
Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
In addition, for applications involving clinical trials
With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
In addition, for applications involving clinical trials
Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?
Approach
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Specific to this FOA: How well does the selection of research projects support the overall goals of the proposed center? Is the rationale for selecting project(s) in basic science and/or behavioral research and/or clinical/health services research appropriate to the overall Center goals? If multiple areas are proposed, how important is pursuit of a larger program to the overall goals? To what extent are the proposed activities likely to enhance the tools for and conduct of research generally and specifically for improving minority health and reducing health disparities at the applicant institution? To what extent are the proposed activities likely to enhance and sustain productive collaborations and partnerships with community-based organizations to promote research efforts and the dissemination of research findings?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
In addition, for applications involving clinical trials
Does the application adequately address the following, if applicable
Study Design
Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?
Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?
Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?
Data Management and Statistical Analysis
Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
Specific to this FOA: How likely is the proposed Center to foster and enhance environments conducive to investigator development, particularly for new and early career investigators? To what extent do the institutional letters of support indicate that the applicant institution is fully committed to achieving the goals and objectives of the proposed Center, and that the Center will be integral to achieving the broad institutional vision for health sciences? Is it clearly described how the Center will leverage existing NIH- or other federally funded projects and resources, including those from NIMHD, NIGMS, NCATS, NIA and other funders to conduct research and disseminate findings?
In addition, for applications involving clinical trials
If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?
Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?
If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?
If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Study Timeline
Specific to applications involving clinical trials
Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?
Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Individuals Across the Lifespan
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
For Renewals, the committee will consider the progress made in the last funding period.
Revisions
Not Applicable
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Not Applicable
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) will not be evaluated at time of review.
Reviewers will comment on whether the Resource Sharing Plan(s) (i.e., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.
Authentication of Key Biological and/or Chemical Resources:
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Overall Impact - Cores
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the Cores collectively to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria. Criterion scores will not be provided for the Cores.
Review Criteria - Cores
Reviewers will consider each of the review criteria below in the determination of scientific merit.
Review Criteria - Administrative Core
Is an appropriate Management Plan provided describing the Center’s organizational and governance structure, including any advisory committees, and strategies for overseeing, managing and coordinating the entire range of proposed Center activities?
Are appropriate measures and procedures proposed for monitoring progress and ensuring that component plans are implemented?
Are the roles and responsibilities of core personnel clearly delineated and appropriate?
Are there adequate institutional plans and procedures to assure compliance with applicable federal regulations and NIH policies for the protection of human research participants, including the evaluation of risks and protections in project proposals, appropriate ethical oversight of funded projects, and plans for monitoring data and safety in clinical research projects?
Is an evaluation plan provided that incorporates appropriate performance targets, objectives, and outcomes?
Review Criteria - Research Capacity Core
Do core personnel have the appropriate background, training and experience to effectively provide the proposed research services and resources?
To what extent are the proposed plans for core operations, management, prioritization and tracking of services, and assessment of the core's effectiveness likely to enhance the quality and productivity of health-related research at the applicant institution? Is there evidence of synergy with the proposed Research Projects and the Pilot Project Program?
Does the description of the potential user pool support the likelihood that the core will enhance institutional capacity for conducting a broad range of health-related research?
Are the proposed resources likely to complement and be integrated with other research resources at the institution and any affiliates?
Are the proposed processes for developing standards and other means to maximize interoperability between internal and external systems feasible and likely to enhance collaborations with other research consortia and networks? Are appropriate plans provided to develop a standard set of common data elements and measures to be used across Research Projects and pilot projects as applicable, including those from the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org)?
Are there well-considered plans for sustaining research capacity (e.g., shared core facilities) through cost recovery and/or institutional support?
Review Criteria - Investigator Development Core
How likely is the proposed Pilot Project Program to promote and enhance career development and transition to independence for post-doctoral fellows, junior faculty and other early-stage investigators (ESIs) consistent with NIH's definition (see https://grants.nih.gov/policy/early-investigators/index.htm#definition)?
Are criteria and procedures for soliciting, submitting, reviewing and selecting pilot projects for funding, including the expected number, distribution, direct costs and duration of pilot projects, clearly described and adequately justified in the overall context of the Center’s proposed objectives?
Are appropriate advisory and technical support resources in place to support rigorous research design, appropriate statistical analyses, and compliance with applicable Federal laws, regulations and policies for research involving human subjects and live vertebrate animals?
To what extent are plans for overseeing and mentoring pilot award recipients, including commitment of the identified mentors, likely to enhance their professional development?
Review Criteria - Community Engagement Core
To what extent are the proposed activities likely to successfully establish or enhance sustainable partnerships with community-based organizations and community members to address their health-related concerns and promote participation in the Center's research activities?
Are plans for dissemination of information to a broad range of audiences well described and consistent with the objectives of the Center?
Are plans to engage in strategic planning processes to translate findings into sustainable community and system-level changes at the local level and beyond described and realistic?
To what extent are the proposed activities likely to contribute to improved interventions based on local knowledge, improved cultural competency of investigators, and strengthened community-engaged research approaches?
Review Criteria - Optional Recruitment Core
If a Recruitment Core is proposed, are plans for recruiting, hiring, and retention of additional research faculty and other personnel adequately justified in terms of accomplishing the goals of the Center?
If applicable, are the proposed investigator development plans likely to enhance the competitiveness of junior faculty and promote their success as independent investigators?
Are the plans supportive to the establishment of a recruited faculty’s research program at the RCMI institution?
Are there appropriate timelines for hiring of new faculty and/or staff members?
Overall Impact - Research Project
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Scored Review Criteria - Research Project
Reviewers will consider each of the review criteria below in the determination of scientific merit and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
In addition, for projects involving clinical trials:
Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?
Investigators
Are the Leads, collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Specific to this FOA: Are the roles of academic and community collaborators, if applicable, clearly described and appropriate?
In addition, for projects involving clinical trials:
With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
In addition, for projects involving clinical trials:
Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?
Approach
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility, and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
Specific to this FOA: For behavioral or clinical/health services research projects that involve human subjects, are plans to reach, recruit, and retain individuals from the target populations adequately described and appropriate?
In addition, for projects involving clinical trials:
Does the application adequately address the following, if applicable:
Study Design
Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?
Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?
Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?
Data Management and Statistical Analysis
Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
In addition, for projects involving clinical trials
If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?
Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?
If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?
Additional Review Criteria Research Project
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Study Timeline
Specific to projects involving clinical trials:
Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate? Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Individuals Across the Lifespan
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Additional Review Considerations Research Project
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Applications from Foreign Organizations
Not Applicable
Resource Sharing Plans
Reviewers will comment on whether the Resource Sharing Plan(s) (i.e., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable.
Authentication of Key Biological and/or Chemical Resources
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIMHD, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Appeals of initial peer review will not be accepted for applications submitted in response to this FOA
Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Minority Health and Health Disparities (NACMHD). The following will be considered in making funding decisions:
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.
Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.
ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain applicable clinical trials on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm
Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).
Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).
Prior Approval of Pilot Projects
Recipient-selected projects that involve human subjects or live vertebrate animals require prior approval by NIH prior to initiation.
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:
If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS will be required to complete an HHS Assurance of Compliance form (HHS 690) in which the recipient agrees, as a term and condition of receiving the grant, to administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, age, sex and disability, and agreeing to comply with federal conscience laws, where applicable. This includes ensuring that entities take meaningful steps to provide meaningful access to persons with limited English proficiency; and ensuring effective communication with persons with disabilities. Where applicable, Title XI and Section 1557 prohibit discrimination on the basis of sexual orientation, and gender identity. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html
HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.
Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75 and 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
The Program Official will:
Areas of Joint Responsibility include:
Dispute Resolution:
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel will be convened, composed of three members: a designee of the Advisory Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
3. Data Management and Sharing
Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.
Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
Progress reports should briefly describe status of pilot projects, including data and safety monitoring, and should notify NIH of serious adverse events and unanticipated problems.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over the threshold. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 and 2 CFR Part 200 Award Term and Condition for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)
Finding Help Online: https://www.era.nih.gov/need-help (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-480-7075
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov
Nathan Stinson, Jr., PhD, MD, MPH
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8704
Email: stinsonn@mail.nih.gov
Rina Das, PhD.
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-496-3996
Email: dasr2@mail.nih.gov
Yujing Liu, MD, PhD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-827-7815
Email: liuyujin@mail.nih.gov
Priscilla Grant, JD
National Institute on Minority Health and Health Disparities (NIMHD)
Telephone: 301-594-8412
Email: grantp@mail.nih.gov
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.